BidaskClub cut shares of Dova Pharmaceuticals (NASDAQ:DOVA) from a hold rating to a sell rating in a report published on Thursday morning.
Separately, Evercore ISI began coverage on shares of Dova Pharmaceuticals in a research report on Friday, March 23rd. They issued a line rating and a $29.00 price objective on the stock. One research analyst has rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the company. The stock currently has an average rating of Hold and an average target price of $32.00.
Dova Pharmaceuticals stock opened at $27.12 on Thursday. The company has a market capitalization of $763.48 and a PE ratio of -19.37. Dova Pharmaceuticals has a twelve month low of $16.98 and a twelve month high of $37.00.
Hedge funds have recently made changes to their positions in the company. The Manufacturers Life Insurance Company lifted its position in shares of Dova Pharmaceuticals by 702.0% in the fourth quarter. The Manufacturers Life Insurance Company now owns 4,756 shares of the company’s stock worth $137,000 after purchasing an additional 4,163 shares in the last quarter. California State Teachers Retirement System bought a new stake in shares of Dova Pharmaceuticals in the third quarter worth $202,000. Schwab Charles Investment Management Inc. bought a new stake in shares of Dova Pharmaceuticals in the third quarter worth $241,000. Virtus Fund Advisers LLC bought a new stake in shares of Dova Pharmaceuticals in the fourth quarter worth $318,000. Finally, Deutsche Bank AG lifted its position in shares of Dova Pharmaceuticals by 139.2% in the fourth quarter. Deutsche Bank AG now owns 11,748 shares of the company’s stock worth $337,000 after purchasing an additional 6,836 shares in the last quarter. 26.05% of the stock is currently owned by institutional investors and hedge funds.
Dova Pharmaceuticals Company Profile
Dova Pharmaceuticals, Inc is a clinical-stage pharmaceutical company. The Company is focused on acquiring, developing and commercializing drug candidates. The Company’s initial focus is on thrombocytopenia, a disorder characterized by a low blood platelet count. The Company is developing avatrombopag for treatment of thrombocytopenia in patients with chronic liver disease (CLD).
Receive News & Ratings for Dova Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dova Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.